FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, b.c. 20045

| <b>STATEMENT</b> | OF CHA | NGES IN | <b>BENEFICIA</b> | AL OWNE |
|------------------|--------|---------|------------------|---------|

| RSHIP | OMB Number:             | 3235-0287 |
|-------|-------------------------|-----------|
| 1.0.1 | Estimated average burde | en        |
|       | hours per response:     | 0.5       |
|       |                         |           |

OMB APPROVAL

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     El-Hibri Fuad  |  |      |   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ] |  |   |   |      |                                      |                    |  | 5. Relationship of Reporting Person(s) to Is<br>(Check all applicable)<br>X Director X 10% C |   |  |   |    | Owner |            |  |
|--|--|------|---|--|--|---|---|------|--------------------------------------|--------------------|--|--|---|--|---|----|-------|------------|--|
| (Last) (First) (Middle) 2401 4TH AVENUE SUITE 1050   |  |      |   | 3. Date of Earliest Transaction (Month/Day/Year) 07/11/2019                          |  |   |   |      |                                      |                    |  |  | Officer (give title Other (special below)  Board of Directors |  |   |    |       |            |  |
| (Street) SEATTL  |  |      | 98121<br>Zip)   |  | - 4. If  | 4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group F Line)  X Form filed by One F Form filed by More Person |   |      |                                      |                    |  |  | e Repo  |  |   |    |       |            |  |
|  |  | Tabl | e I - N   | on-Deriv   | ative  | Seci  | uritie  | s Ac | quire                                | d, Di              | sposed o   | f, or E  | enefic  | ally   | Owne  | ed |       |            |  |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/   |  |      |   | Execution Date,  |  | 3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 and 1)   |   |      | ed (A) or<br>tr. 3, 4 and            | nd 5) Secu<br>Bene |  | icially<br>d Following   | Form:   | nership<br>Direct<br>Indirect<br>str. 4)                           | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |    |       |            |  |
|  |  |      |   |  |  |   |   | Code | v                                    | Amount             | (A) or<br>(D)  | Price  |   | Trans  | ransaction(s)<br>Instr. 3 and 4)                                  |    |       | (111311.4) |  |
| Common Stock 07/11/20  |  |      | 2019  |  |  |   | P   |      | 14,691                               | A                  | \$0.84   | 477 <sup>(1)</sup> 858,146 D   |   |  |   |    |       |            |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |      |   |  |  |   |   |      |                                      |                    |  |  |   |  |   |    |       |            |  |
| Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any   |  |      | saction le (Instr. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |  | 6. Date Exercisable and Expiration Date (Month/Day/Year) |   | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr. 3<br>and 4)  Amount<br>or<br>Number<br>of |      | Derivative<br>Security<br>(Instr. 5) |                    | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) |  | vnership<br>orm:<br>rect (D)<br>Indirect<br>(Instr. 4)        | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |    |       |            |  |

## Explanation of Responses:

1. The purchase price of \$0.8477 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from \$0.84 to \$0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

## Remarks:

<u>/s/ El-Hibri, Faud</u> <u>07/12/2019</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.